Amberstone Biosciences, Inc. Deal History & Licensing Activity
Amberstone Biosciences, Inc. is a biotech. Over the past three years, Amberstone Biosciences, Inc. has been involved in 2 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Other
Amberstone Biosciences, Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Amberstone Biosciences, Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| T-cell engager program | Henlius | Bispecific Antibodies | Unknown | license | Sep 24, 2026 |
| Undisclosed | Shanghai Henlius Biotech, Inc. | Bispecific Antibodies | Discovery | collaboration | Sep 23, 2026 |
Amberstone Biosciences, Inc. Pipeline Focus
Therapeutic areas and modalities where Amberstone Biosciences, Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Amberstone Biosciences, Inc.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Amberstone Biosciences, Inc. Licensing & Deal Activity
Amberstone Biosciences, Inc. is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Amberstone Biosciences, Inc. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Amberstone Biosciences, Inc. include Other (2 deals and trials), and Oncology (2 deals and trials). In terms of modality, Amberstone Biosciences, Inc. has shown particular interest in bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Amberstone Biosciences, Inc. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Amberstone Biosciences, Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.